PMID- 27159666
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20220321
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
VI  - 54
IP  - 11
DP  - 2016 Nov
TI  - Reduced colorectal cancer incidence in type 2 diabetic patients treated with 
      metformin: a meta-analysis.
PG  - 2636-2642
AB  - CONTEXT: Diabetic patients have a higher risk of colorectal cancer (CRC). The 
      role of metformin in CRC incidence among type 2 diabetes mellitus (T2DM) remains 
      controversial. OBJECTIVE: A meta-analysis was performed to evaluate the role of 
      metformin treatment in the occurrence of CRC among T2DM patients. METHODS: Search 
      was performed throughout PubMed, Embase, Springer databases up to November 2014. 
      The search terms were (biguanides or metformin) and (bowel or colon or rectal or 
      colorectal) and (cancer or neoplasm or neoplasia). Relative risk (RR) and 95% 
      confidence interval (CI) was pooled using random-effects model or fixed-effect 
      model basing on heterogeneity, which was calculated basing on Q statistics and 
      chi(2) test. In addition, subgroup analyses were performed according to region, 
      study design and control treatment. Finally, publication bias was evaluated using 
      Egger's regression test and trim and fill analysis. RESULTS: A total of 11 
      studies, including eight cohort studies and three case-control studies, were 
      enrolled in the meta-analysis. Obvious heterogeneity was noted, and a 25% lower 
      CRC incidence was found among diabetic patients treated with metformin (pooled 
      RR=0.75, 95% CI: 0.66-0.86), using the random-effects model. Subgroup analyses 
      showed that CRC incidence significantly reduced among T2DM in different regions, 
      non-metformin treatment and cohort studies. Evidence supported significant 
      publication for studies investigating from Egger's regression test. Conversely, 
      no missing data were found using trim and fill analysis. CONCLUSION: In 
      conclusion, the meta-analysis suggests metformin may reduce CRC incidence among 
      diabetics, which is useful medical information for clinicians.
FAU - Nie, Zhihong
AU  - Nie Z
AD  - a Department of Gastroenterology , Shanghai Pudong New Area Gongli Hospital , 
      Shanghai , China.
FAU - Zhu, Hongling
AU  - Zhu H
AD  - b Department of Endocrine , Shanghai Pudong New Area Gongli Hospital , Shanghai , 
      China.
FAU - Gu, Mingjun
AU  - Gu M
AD  - b Department of Endocrine , Shanghai Pudong New Area Gongli Hospital , Shanghai , 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160509
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Colorectal Neoplasms/*prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Metformin/*therapeutic use
MH  - Publication Bias
OTO - NOTNLM
OT  - Egger's regression test
OT  - trims and fill analysis
OT  - type 2 diabetic mellitus
EDAT- 2016/05/10 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/05/10 06:00
PHST- 2016/05/10 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/05/10 06:00 [entrez]
AID - 10.1080/13880209.2016.1176057 [doi]
PST - ppublish
SO  - Pharm Biol. 2016 Nov;54(11):2636-2642. doi: 10.1080/13880209.2016.1176057. Epub 
      2016 May 9.